Abstract:We investigated the potential correlation between the characteristics prior transplantation and the subsequent clinical outcomes in 175 consecutive patients who received HSC transplantation from HLA-mismatched/haploidentical donors. Patients eligible for study were those with a diagnosis of leukemia, all lacking an HLA matched sibling or unrelated donor. Patients ranged in age from 6 to 53 years (median 25 years) and donors from 13 to 66 years (median 40 years). Compatibility testing of family members included serology and intermediate resolution DNA typing for HLA-A, -B, and -C antigens, plus high resolution DNA typing for HLA-DRB1, -DQB1, and -DPB1. Donors included 72 mothers (41%), 29 fathers (16.6%), 54 siblings (31%), 16 children (9%), 4 cousins (2.3%), with various grades of HLA disparity: 28 (16%) with 1; 79 (45%) with 2; 68 (39%) with 3 antigen mismatch. Grafts (BM+PB) was harvested from donor BM collected after four days of G-CSF, and PB collected after 5 days of G-CSF. The graft was analyzed for content of CD34+ cells and subsets of lymphoid cell populations, CD3+, CD4+, CD8+, and CD14+, using standardized Multi-set kits (Becton-Dickinson, San Jose, CA, USA). All patients enrolled in this study were treated with a uniform conditioning regimen (BuCy2+ATG), given GVHD prophylaxis (CsA+ short term MTX), and followed from 36 to 1191days after transplantation (median 401 days). Univariate analysis for survival indicated that disease status prior transplantation and donor CD3+ cell dose were the only predictors of the 2-year probability of survival: early disease (77.8%), intermediate disease (38%), and those with advanced disease (52%), [P=0.018]; survival in those given a CD3+ cell dose <150 ×106/kg was 52% and CD3+ cell dose ≥150×106/kg was 74%, respectively [P=0.0215]. This was confirmed by multivariate analysis: patients transplanted with intermediate/advanced stage disease [RR=1.568 (95% CI, 1.128-2.17); P=0.007] had a worse overall survival; Infusion of a high dose of CD3+ cells (≥150 × 106/kg) had improved survival [0.530 (0.300-0.95); P=0.03] without increase the incidence of developing Grade 3-4 aGVHD [1.27 (0.58-2.76); P=0.56]. Our data have indicated that with the current protocol, patients given a relatively high dose of CD3+ cells (≥150×106/kg) have a significantly better overall survival after transplantation than those given lower doses of CD3+ cells (<150 ×106/kg).

The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT

Impact of HLA High-Resolution Matching on Outcomes of Myeloablative Unrelated Donor Hematopoietic Stem Cell Transplantation in Chinese Population

The Impact of Graft Composition on Clinical Outcomes in Pediatric Patients Undergoing Unmanipulated Hla-Mismatched/Haploidentical Hematopoietic Stem Cell Transplantation

Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant.

High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia

An Unbalanced Monocyte Macrophage Polarization In The Bone Marrow Microenvironment Of Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia: Effects of CD34+ and CD14+ Cell Doses

Association of Natural Killer Cells in Allografts with Transplant Outcomes in Patients Receiving G-Csf-Mobilized Pbsc Grafts and G-Csf-Primed Bm Grafts from Hla-Haploidentical Donors

338: Effect of CD3+ Cell Dose on Outcome in Patients after Conditioning Including Antithymocyte Globulin Followed by Un-Manipulated HLA-mismatched/haploidentical Blood and Marrow Transplantation

Expression of CD62L on Donor CD4 + T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation

Impact of donor-to-recipient ABO mismatch on outcomes of ATG-based peripheral blood stem cell-derived myeloablative conditioning haploidentical stem cell transplantation

Improved outcomes using <scp>G‐CSF</scp>‐mobilized blood and bone marrow grafts as the source of stem cells compared with <scp>G‐PB</scp> after <scp>HLA</scp>‐identical sibling transplantation in patients with acute leukemia

The Inferiority of G-PB to Rhg-Csf-mobilized Blood and Marrow Grafts As a Stem Cell Source in Patients with High-Risk Acute Leukemia Who Underwent Unmanipulated HLA-mismatched/haploidentical Transplantation: a Comparative Analysis

Effect of Rhg-Csf Mobilized Peripheral Blood and Bone Marrow after Being Mixed in Different Proportions on Immunologic Properties of Grafts

Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation.

Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia.

Influence of the Degree of Donor Bone Marrow Hyperplasia on Patient Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation

Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome

Analysis of 66 Cases Received Hematopoietic Stem Cell Transplantation from Unrelated Donors

Negative Association of Donor Age with Cd34(+) Cell Dose in Mixture Allografts of G-Csf-Primed Bone Marrow and G-Csf-Mobilized Peripheral Blood Harvests

[Effect of Graft-Versus-host Disease on Relapse and Survival in 100 Patients after Allogeneic Hematopoietic Stem Cell Transplantation].